(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2014 (15.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/072888 A1

(51) International Patent Classification:
A61K 47/48 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/IB2013/059786

(22) International Filing Date:
30 October 2013 (30.10.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/723,545	7 November 2012 (07.11.2012)	US
61/749,610	7 January 2013 (07.01.2013)	US
61/886,156	3 October 2013 (03.10.2013)	US
61/889,179	10 October 2013 (10.10.2013)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **MA, Dangshe**; 49 Glenwood Road, Millwood, New York 10546 (US). **JIN, Fang**; 353 Woodward Street, Waban, Massachusetts 02468 (US). **TCHISTIAKOVA, Lioudmila, Gennadievna**; 3 O'Grady Circle, Stoneham, Massachusetts 02180 (US). **SAPRA, Puja**; 254 Wayne Avenue, River Edge, New Jersey 07661 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-IL-13 RECEPTOR ALPHA 2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

(57) Abstract: Disclosed herein are anti-IL-13-Rα2 antibodies and antibody drug conjugates and methods for preparing and using the same.

FIG. 2A



WO 2014/072888 A1

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*